HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account

Clinical Expertise

  • DLBCL Specialist

About

Prof. Younes has spent more than 25 years caring for patients with lymphoma and lead numerous clinical trials that advanced the field. His research resulted in the US Food and Drug Administration approval of two novel agents for patients with Hodgkin lymphoma, including the first targeted drug for the treatment of Hodgkin lymphoma in more than three decades (brentuximab vedotin), and the approval of the first immune checkpoint inhibitor for lymphoma (nivolumab).

Location

MD Anderson Cancer Center: 1515 Holcombe Blvd, Houston, TX 77030, USA

Get the latest thought leadership on Diffuse Large B Cell Lymphoma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Diffuse Large B Cell Lymphoma Newsletter" for Diffuse Large B Cell Lymphoma news, life with Diffuse Large B Cell Lymphoma stories, Diffuse Large B Cell Lymphoma clinical trials, Diffuse Large B Cell Lymphoma 101 articles and events with Diffuse Large B Cell Lymphoma experts.

Thanks to our HealthTree Community for Diffuse Large B Cell Lymphoma Sponsors:

Regeneron